The effect of 1-furan-2-yl-3-pyridine-2-yl-propenone on pharmacokinetic parameters of theophylline

Biological and Pharmaceutical Bulletin

Volumn 29, Issue 6, 2006, Pages 1282-1285

  Shanmugam, Srinivasan ^a   Lee, Eung Seok ^a   Lee, Sang Kyu ^a   Jeon, Tae Won ^a   Yong, Chul Soon ^a   Yoo, Bong Kyu ^a  

^a Yeungnam University   (South Korea)

Author keywords

1 furan 2 yl 3 pyridine 2 yl propenone; Cytochrome P450; Drug interaction; Pharmacokinetic parameters; Theophylline

Indexed keywords

1 FURAN 2 YL 3 PYRIDINE 2 YL PROPENONE; ARACHIDONATE 5 LIPOXYGENASE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; ETHOXYRESORUFIN DEETHYLASE; LIPOXYGENASE INHIBITOR; METHOXYRESORUFIN O DEMETHYLASE; METHYLTRANSFERASE; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; THEOPHYLLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYMATIC ASSAY; ENZYME ACTIVITY; ENZYME INHIBITION; LONG TERM CARE; MALE; NONHUMAN; PRESCRIPTION; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FURANS; MALE; PROPANE; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; THEOPHYLLINE; TIME FACTORS;

EID: 33744915263     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.29.1282     Document Type: Article

References (18)

1. Fiorucci S., Meli R., Bucci M., Cirino G., Biochem. Pharmacol., 62, 1433-1438 (2001).
2. Fosslien E., Ann. Clin. Lab. Sci., 35, 347-385 (2005).
3. Takeuchi K., Tanaka A., Hayashi Y., Yokota A., Curr. Top. Med. Chem., 5, 475-486 (2005).
4. Whelton A., Am. J. Ther., 7, 63-74 (2000).
5. Wolfe F., Anderson J., Burke T., Arguelles L., Pettitt D., J. Rheumatol., 29, 467-473 (2002).
6. Schmedtje J., Ji Y., Liu W., DuBois R., Runge M., J. Biol. Chem., 272, 601-608 (1997).
7. Belton O., Byrne D., Kearney D., Leahy A., Fitzgerald D., Circulation, 102, 840-845 (2000).
8. Burnier M., Expert Opin. Drug Saf., 4, 491-499 (2005).
9. Jahng Y., Zhao L., Moon Y., Basnet A., Kim E., Chang H., Ju H., Jeong T., Lee E., Bioorg. Med. Chem. Lett., 14, 2559-2562 (2004).
10. Lee E., Ju H., Moon T., Lee E., Jahng Y., Lee S., Son J., Baek S., Chang H., Biol. Pharm. Bull., 27, 617-620 (2004).
11. Blank J., Tucker A., Sweatlock J., Gasiewicz T., Luster M., Mol. Pharmacol., 32, 169-172 (1987).
12. Koch K., Ricci B., Hedayetullah N., Jewell D., Kersey K., J. Clin. Pharmacol., 52, 596-600 (2001).
13. Lee S., Jeon T., Basnet A., Lee E., Jeong T., Arch. Pharm. Res., submitted (2006).
14. Gu L., Gonzalez F., Kalow W., Tang B., Pharmacogenetics, 2, 73-77 (1992).
15. Tassaneeyakul W., Birkett D., McManus M., Tassaneeyakul W., Veronese M., Andersson T., Tukey R., Miners J., Biochem. Pharmacol., 47, 1767-1776 (1994).
16. Danie W., Syrek M., Rylko Z., Wojcikowski J., Pol. J. Pharmacol., 53, 351-357 (2001).
17. Sproule B., Naranjo C., Brenmer K., Hassan P., Clin. Pharmacokinet., 33, 454-471 (1997).
18. Derkenne S., Curran C., Shertzer H., Dalton T., Dragin N., Nebert D., Pharmacogenet. Genomics, 15, 503-511 (2005).